Sight from ... Sound

TUG

Therapeutic
Ultrasound
for
Glaucoma

Glaucoma

More than 80 million cases in 2020 Estimated 112 million cases by 2040
28% increase of primary open-angle glaucoma in the US per decade to approximately 7.32 million by 2050
50% of persons with early stage glaucoma are unaware that they have the disease
#1 Cause of Irreversible Blindness Worldwide

Breakthrough Therapy

  • One Time, 10 Minute Treatment

  • No Pressure Spikes, Well Tolerated

  • Replace or Supplement Medications

4 out of 5 Treated eyes show an increased thickness of the Retinal Nerve Fiber Layer

An Effective Solution

Comparable results to SLT for treatment with patients currently on medications.

80% of treatment naïve patients had ≥ 20% IOP reduction from baseline at 12 month follow-up.

  • Use for most glaucoma variants

  • Minimal equipment required

  • Non-invasive / Ab externo

TUG Patient Testimonial

Meet Our Team

DONALD SCHWARTZ, OD, MD
President and Founder
ERIC SCHULTZ, MS

CEO, CTO and Co-Founder

OMID KHODAI, OD, MS
Clinical & Regulatory

EyeSonix's team strives to extend "sighted life" worldwide by making available a simple and highly effective glaucoma treatment, breaking the paradigm of present day glaucoma care.

ALAN ROBIN, MD, PA
Clinical Advisor
VINCENT M. PATELLA, OD
Medical Advisor
JOHN SAMPLES, MD
Medical Advisor
JAGDEEP KAKADIA, MD, PhD

Medical Advisor

DARYL MICHALIK, MBA

Business Development

STEPHANIE KAPLAN, MBA
Operations & Quality
RAMESH SHAH, MD
Medical Advisor

Contact Us

If you're interested in hearing more about the technology, have a business proposal, or are interested in making a purchase, we'd love to hear from you.